After demonstrating specificity for KDM1A and anti-cancer and pro-differentiation activities in preclinical models (reviewed in [5]), a total of nine LSD1 inhibitors have entered clinical trials for hematological and/or solid cancers. Here, KDM1A is linked to cancer.